OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
New Orleans-Ruboxistaurin mesylate, a protein kinase C (PKC) beta inhibitor, reduces loss of vision in patients with moderate-ly severe to very severe nonproliferativediabetic retinopathy, researchers reported at the American Diabetes Association meet-ing here.